- Home
- GOSS vs HRZN Comparison
GOSS vs HRZN Comparison
Compare GOSS & HRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- HRZN
- Stock Information
- Founded
- GOSS 2015
- HRZN 2008
- Country
- GOSS United States
- HRZN United States
- Employees
- GOSS N/A
- HRZN N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- HRZN Finance/Investors Services
- Sector
- GOSS Health Care
- HRZN Finance
- Exchange
- GOSS Nasdaq
- HRZN Nasdaq
- Market Cap
- GOSS 347.8M
- HRZN 324.5M
- IPO Year
- GOSS 2019
- HRZN 2010
- Fundamental
- Price
- GOSS $1.84
- HRZN $8.28
- Analyst Decision
- GOSS Strong Buy
- HRZN Hold
- Analyst Count
- GOSS 4
- HRZN 5
- Target Price
- GOSS $8.25
- HRZN $9.15
- AVG Volume (30 Days)
- GOSS 3.6M
- HRZN 489.0K
- Earning Date
- GOSS 08-11-2025
- HRZN 08-05-2025
- Dividend Yield
- GOSS N/A
- HRZN 15.94%
- EPS Growth
- GOSS N/A
- HRZN N/A
- EPS
- GOSS N/A
- HRZN N/A
- Revenue
- GOSS $124,590,000.00
- HRZN $98,302,000.00
- Revenue This Year
- GOSS N/A
- HRZN $1.42
- Revenue Next Year
- GOSS $65.50
- HRZN $4.42
- P/E Ratio
- GOSS N/A
- HRZN N/A
- Revenue Growth
- GOSS N/A
- HRZN N/A
- 52 Week Low
- GOSS $0.66
- HRZN $7.09
- 52 Week High
- GOSS $1.94
- HRZN $12.33
- Technical
- Relative Strength Index (RSI)
- GOSS 70.54
- HRZN 63.37
- Support Level
- GOSS $1.67
- HRZN $7.95
- Resistance Level
- GOSS $1.94
- HRZN $8.46
- Average True Range (ATR)
- GOSS 0.14
- HRZN 0.21
- MACD
- GOSS 0.04
- HRZN 0.04
- Stochastic Oscillator
- GOSS 86.81
- HRZN 80.65
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About HRZN Horizon Technology Finance Corporation
Horizon Technology Finance Corp is a specialty finance company. Its investment objective is to maximize its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It lends to and invests in development-stage companies in the technology, life science, healthcare information and services, and sustainability industries.